Logo image of FTRE

FORTREA HOLDINGS INC (FTRE) Stock Fundamental Analysis

USA - NASDAQ:FTRE - US34965K1079 - Common Stock

9.675 USD
-1.07 (-10%)
Last: 10/10/2025, 9:30:28 PM
9.59 USD
-0.09 (-0.88%)
After Hours: 10/10/2025, 9:30:28 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FTRE. FTRE was compared to 56 industry peers in the Life Sciences Tools & Services industry. FTRE may be in some trouble as it scores bad on both profitability and health. FTRE has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FTRE was profitable.
FTRE had a negative operating cash flow in the past year.
In multiple years FTRE reported negative net income over the last 5 years.
Each year in the past 5 years FTRE had a positive operating cash flow.
FTRE Yearly Net Income VS EBIT VS OCF VS FCFFTRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

With a Return On Assets value of -36.22%, FTRE is not doing good in the industry: 80.36% of the companies in the same industry are doing better.
FTRE has a worse Return On Equity (-174.29%) than 87.50% of its industry peers.
Industry RankSector Rank
ROA -36.22%
ROE -174.29%
ROIC N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
FTRE Yearly ROA, ROE, ROICFTRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

FTRE has a Gross Margin of 19.73%. This is amonst the worse of the industry: FTRE underperforms 83.93% of its industry peers.
In the last couple of years the Gross Margin of FTRE has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for FTRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
FTRE Yearly Profit, Operating, Gross MarginsFTRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

1

2. Health

2.1 Basic Checks

FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
FTRE has more shares outstanding than it did 1 year ago.
The debt/assets ratio for FTRE has been reduced compared to a year ago.
FTRE Yearly Shares OutstandingFTRE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
FTRE Yearly Total Debt VS Total AssetsFTRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 0.49, we must say that FTRE is in the distress zone and has some risk of bankruptcy.
FTRE has a Altman-Z score of 0.49. This is in the lower half of the industry: FTRE underperforms 69.64% of its industry peers.
FTRE has a Debt/Equity ratio of 1.87. This is a high value indicating a heavy dependency on external financing.
FTRE has a worse Debt to Equity ratio (1.87) than 83.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.87
Debt/FCF N/A
Altman-Z 0.49
ROIC/WACCN/A
WACC10.05%
FTRE Yearly LT Debt VS Equity VS FCFFTRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

A Current Ratio of 1.02 indicates that FTRE should not have too much problems paying its short term obligations.
The Current ratio of FTRE (1.02) is worse than 87.50% of its industry peers.
FTRE has a Quick Ratio of 1.02. This is a normal value and indicates that FTRE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.02, FTRE is doing worse than 80.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
FTRE Yearly Current Assets VS Current LiabilitesFTRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

FTRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.22%, which is quite impressive.
Looking at the last year, FTRE shows a decrease in Revenue. The Revenue has decreased by -4.96% in the last year.
Measured over the past years, FTRE shows a decrease in Revenue. The Revenue has been decreasing by -4.10% on average per year.
EPS 1Y (TTM)72.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%733.33%
Revenue 1Y (TTM)-4.96%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%7.23%

3.2 Future

The Earnings Per Share is expected to grow by 42.26% on average over the next years. This is a very strong growth
Based on estimates for the next years, FTRE will show a small growth in Revenue. The Revenue will grow by 1.53% on average per year.
EPS Next Y66.1%
EPS Next 2Y64.86%
EPS Next 3Y53.09%
EPS Next 5Y42.26%
Revenue Next Year-2.61%
Revenue Next 2Y-1.44%
Revenue Next 3Y0%
Revenue Next 5Y1.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FTRE Yearly Revenue VS EstimatesFTRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
FTRE Yearly EPS VS EstimatesFTRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

FTRE is valuated correctly with a Price/Earnings ratio of 15.60.
Based on the Price/Earnings ratio, FTRE is valued cheaply inside the industry as 91.07% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of FTRE to the average of the S&P500 Index (27.02), we can say FTRE is valued slightly cheaper.
A Price/Forward Earnings ratio of 10.47 indicates a reasonable valuation of FTRE.
Based on the Price/Forward Earnings ratio, FTRE is valued cheaper than 98.21% of the companies in the same industry.
FTRE's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.57.
Industry RankSector Rank
PE 15.6
Fwd PE 10.47
FTRE Price Earnings VS Forward Price EarningsFTRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

FTRE's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 252.51
FTRE Per share dataFTRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FTRE's earnings are expected to grow with 53.09% in the coming years.
PEG (NY)0.24
PEG (5Y)N/A
EPS Next 2Y64.86%
EPS Next 3Y53.09%

More info and screens

0

5. Dividend

5.1 Amount

FTRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTREA HOLDINGS INC

NASDAQ:FTRE (10/10/2025, 9:30:28 PM)

After market: 9.59 -0.09 (-0.88%)

9.675

-1.07 (-10%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners112.28%
Inst Owner Change0%
Ins Owners0.34%
Ins Owner Change31.69%
Market Cap878.49M
Analysts53.75
Price Target7.8 (-19.38%)
Short Float %12.36%
Short Ratio6.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)162.11%
Min EPS beat(2)126.66%
Max EPS beat(2)197.56%
EPS beat(4)2
Avg EPS beat(4)65.68%
Min EPS beat(4)-51.68%
Max EPS beat(4)197.56%
EPS beat(8)3
Avg EPS beat(8)-57.12%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.8%
Min Revenue beat(2)4.96%
Max Revenue beat(2)10.63%
Revenue beat(4)2
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-2.83%
Max Revenue beat(4)10.63%
Revenue beat(8)3
Avg Revenue beat(8)-1.24%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.87%
PT rev (3m)28.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.05%
EPS NY rev (1m)-1.67%
EPS NY rev (3m)16.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.57%
Revenue NY rev (1m)-0.3%
Revenue NY rev (3m)4.68%
Valuation
Industry RankSector Rank
PE 15.6
Fwd PE 10.47
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB N/A
EV/EBITDA 252.51
EPS(TTM)0.62
EY6.41%
EPS(NY)0.92
Fwd EY9.55%
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS30.1
BVpS6.49
TBVpS-11.35
PEG (NY)0.24
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.22%
ROE -174.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.73%
FCFM N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score3
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.87
Debt/FCF N/A
Debt/EBITDA 134.26
Cap/Depr 18.99%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z 0.49
F-Score3
WACC10.05%
ROIC/WACCN/A
Cap/Depr(3y)43.05%
Cap/Depr(5y)33.05%
Cap/Sales(3y)1.37%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%733.33%
EPS Next Y66.1%
EPS Next 2Y64.86%
EPS Next 3Y53.09%
EPS Next 5Y42.26%
Revenue 1Y (TTM)-4.96%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%7.23%
Revenue Next Year-2.61%
Revenue Next 2Y-1.44%
Revenue Next 3Y0%
Revenue Next 5Y1.53%
EBIT growth 1Y-39.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.82%
EBIT Next 3Y10.43%
EBIT Next 5Y11.67%
FCF growth 1Y85.25%
FCF growth 3Y18.31%
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3Y15.67%
OCF growth 5YN/A